Related Experiment Videos
Prospects: histone deacetylase inhibitors
Milos Dokmanovic1, Paul A Marks
1Memorial Sloan-Kettering Cancer Center, Cell Biology Program, Sloan Kettering Institute for Cancer Research New York City, New York 10021, USA.
Journal of Cellular Biochemistry
|August 10, 2005
Summary
Histone deacetylase (HDAC) inhibitors are promising anti-cancer drugs that induce cancer cell death. Understanding their mechanisms, including why tumors respond differently, can improve their efficacy and safety.
Area of Science:
- Epigenetics
- Molecular Biology
- Cancer Therapeutics
Background:
- Histone deacetylase (HDAC) inhibitors are emerging targeted anti-cancer agents.
- These compounds show significant activity in clinical trials against various cancers.
- HDAC inhibitors induce cancer cell growth arrest, differentiation, and apoptosis.
Purpose of the Study:
- To explore the mechanism of action of HDAC inhibitors (HDACi).
- To investigate the differential response of normal versus cancer cells to HDACi.
- To understand tumor-specific responses and gene expression alterations induced by HDACi.
Main Methods:
- Review of current literature on HDAC inhibitors.
- Analysis of epigenetic gene regulation by histone acetylation and deacetylation.
- Examination of HDACs and histone acetyltransferases (HATs) as key enzymes.
Main Results:
- HDAC inhibitors induce diverse cancer cell phenotypes.
- Normal cells exhibit relative resistance to HDACi-induced cell death compared to cancer cells.
- Tumor responsiveness to HDACi varies, influenced by altered gene expression and cell functions.
Conclusions:
- Understanding HDACi mechanisms is crucial for enhancing anti-cancer therapy.
- Identifying targets for HDACi can improve treatment efficacy and patient safety.
- Further research into HDACi selectivity and action is vital for therapeutic advancements.